Recent Updates
Recently added Catalysts
COLL Positive Sentiment Score: 70/100

Collegium to Participate in Upcoming Investor Conferences

Thursday, August 28, 2025 2 min read
Key Takeaway: Collegium Pharmaceutical, Inc. announced its participation in several upcoming investor conferences, including the Wells Fargo Healthcare Conference and the Morgan Stanley Global Healthcare Conference. The company aims to showcase its investment potential and growth strategy during these events. A live webcast of the presentations will be available on its website, with replays accessible for 90 days. Collegium is focused on enhancing its diverse biopharmaceutical portfolio, particularly in pain management and neuropsychiatry.

Market Sentiment Analysis

POSITIVE FACTORS

  • Management is actively engaging with investors at multiple conferences.
  • Collegium has a strong portfolio in pain management and ADHD treatments.
  • The company's strategy focuses on disciplined capital deployment and portfolio growth.

Full Press Release Details

STOUGHTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences:
2025 Wells Fargo Healthcare Conference
Thursday, September 4, 2025
Morgan Stanley 23rd Annual Global Healthcare Conference
Fireside Chat Date and Time: Monday, September 8, 2025 at 2:35 p.m. ET
A live webcast of the fireside chat will be available via the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
H.C. Wainwright 27th Annual Global Investment Conference
Fireside Chat Date and Time: Tuesday, September 9, 2025 at 10:30 a.m. ET
A live webcast of the fireside chat will be available via the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
About Collegium Pharmaceutical, Inc.
Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and a rapidly growing neuropsychiatry business driven by Jornay PM®, a differentiated treatment for ADHD. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.
Head of Investor Relations
ir@collegiumpharma.com
Director, Investor Relations
ir@collegiumpharma.com
Head of Corporate Communications
communications@collegiumpharma.com

Frequently Asked Questions

What conferences will Collegium Pharmaceuticals attend?

Collegium Pharmaceuticals will participate in the Wells Fargo Healthcare Conference and Morgan Stanley's Global Healthcare Conference.

When is the fireside chat at the Morgan Stanley conference?

The fireside chat at the Morgan Stanley conference is on September 8, 2025, at 2:35 p.m. ET.

How long will the webcast replay be available?

The webcast replay will be available for 90 days after the presentation.

What is Collegium's main focus as a biopharmaceutical company?

Collegium focuses on responsible pain management medications and neuropsychiatry.

What is Jornay PM®?

Jornay PM® is Collegium's standout treatment for ADHD, driving their growth strategy.

Tags: COLL Viatris Investor Conferences Healthcare Collegium Pharmaceutical investor conferences neuropsychiatry pain management
Last updated: Aug 28, 2025